Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis

American Journal of Gastroenterology

Volumn 99, Issue 12, 2004, Pages 2385-2392

  Katz, Jeffry A ^a   Antoni, Christian ^b   Keenan, Gregory F ^b   Smith, Deirdre E ^b   Jacobs, Stephen J ^b   Lichtenstein, Gary R ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; HISTAMINE H2 RECEPTOR ANTAGONIST; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; BIRTH; CONTROLLED STUDY; CROHN DISEASE; DISEASE COURSE; DRUG INDICATION; DRUG SAFETY; FEMALE; FETUS; FETUS RISK; FOLLOW UP; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PREGNANCY COMPLICATION; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SPONTANEOUS ABORTION; UNITED STATES;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHI-SQUARE DISTRIBUTION; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; PREGNANCY; PREGNANCY OUTCOME;

EID: 11144266570     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2004.30186.x     Document Type: Article

References (52)

1. Lügering A, Schmidt M, Lügering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001;121:1145-57.
2. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor (alpha) for Crohn's disease. N Engl J Med 1997;337:1029-35.
3. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
4. Lipsky PE, van der Heijde DM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
5. Baiocco PJ, Korelitz BI. The influence of inflammatory bowel disease and its treatment on pregnancy and fetal outcome. J Clin Gastroenterol 1984;6:211-6.
6. Fonager K, Sorensen HT, Olsen J, et al. Pregnancy outcome for women with Crohn's disease: A follow-up study based on linkage between national registries. Am J Gastroenterol 1998;93:2426-30.
7. Miller JP. Inflammatory bowel disease in pregnancy: A review. J R Soc Med 1986;79:221-5.
8. Mogadam M, Korelitz BI, Ahmed SW, et al. The course of inflammatory bowel disease during pregnancy and postpartum. Am J Gastroenterol 1981;75:265-9.
9. Alstead EM, Nelson-Piercy C. Inflammatory bowel disease in pregnancy. Gut 2003;52:159-61.
10. Osrtensen M. The effect of pregnancy on ankylosing spondylitis, psoriatic arthritis, and juvenile rheumatoid arthritis. Am J Reprod Immunol 1992;28:235-7.
11. Barrett JH, Brennan P, Fiddler M, et al. Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Arthritis Rheum 1999;42:1219-27.
12. Treacy G. Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFα monoclonal antibody. Hum Exp Toxicol 2000;19:226-8.
13. James RL, Pearson LL. Successful treatment of pregnancy-triggered Crohn's disease complicated by severe recurrent life-threatening gastrointestinal bleeding [abstract]. Am J Gastroenterol 2001;296:S295.
14. Srinivasan R. Infliximab treatment and pregnancy outcome in active Crohn's disease. Am J Gastroenterol 2001;96:2274-5.
15. Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying antirheumatic drugs in women with rheumatic arthritis of childbearing age: A survey of practice patterns and pregnancy outcomes. J Rheumatol 2003;30:241-6.
16. Ventura SJ, Mosher WD, Curtin SC, et al. Trends in pregnancies and pregnancy rates by outcome: Estimates for the United States, 1976-96. Vital Health Stat 21. 2000:Jan;(56):1-47.
17. Hudson M, Flett G, Sinclair TS, et al. Fertility and pregnancy in inflammatory bowel disease. Int J Gynaecol Obstet 1997;58:229-37.
18. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-69.
19. Braun J, Brandt J, Listing J, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Arthritis Rheum 2003;48:2224-33.
20. Katz JA, Pore G. Inflammatory bowel disease and pregnancy. Inflamm Bowel Dis 2001;7:146-57.
21. Armenti VT, Ahlswede KM, Ahlswede BA, et al. National transplantation pregnancy registry - Outcomes of 154 pregnancies in cyclosporine-treated female kidney transplant recipients. Transplantation 1994;57:502-6.
22. Bulmash JM. Rheumatoid arthritis and pregnancy [Review]. Obstet Gynaecol Annu 1979;8:223-76.
23. Mogadam M, Dobbins WO, Korelitz BI, et al. Pregnancy in inflammatory bowel disease: Effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 1981;80:72-6.
24. Bell CM, Habal FM. Safety of topical 5-aminosalicylic acid in pregnancy. Am J Gastroenterol 1997;92:2201-2.
25. Habal FM, Hui G, Greenberg GR. Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: Safety and clinical course. Gastroenterology 1993;105:1057-60.
26. Diav-Citrin O, Park YH, Veerasuntharam G, et al. The safety of mesalamine in human pregnancy: A prospective controlled cohort study. Gastroenterology 1998;114:23-8.
27. Alstead EM, Ritchie JK, Lermard-Jones JE, et al. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990;99:443-6.
28. Francella A, Dyan A, Bodian C, et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: A retrospective cohort study. Gastroenterology 2003;124:9-17.
29. Kane SV. What's good for the goose should be good for the gander-6-MP use in fathers with inflammatory bowel disease. Am J Gastroenterol 2000;95:581-2.
30. Rajapaske RO, Korelitz BI, Zlatanic J, et al. Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol 2000;95:684-8.
31. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk, 5th Ed. Baltimore: Williams & Wilkins, 1998:702-6.
32. Donnenfeld AE, Pastuszak A, Noah JS, et al. Methotrexate exposure prior to and during pregnancy. Teratology 1994;49:79-81.
33. BertschingerP, Himmelmann A, Risti B, et al. Cyclosporine treatment of severe ulcerative colitis during pregnancy. Am J Gastroenterol 1995;90:330.
34. Marion JF, Rubin PH, Lichtiger S, et al. Cyclosporine is safe for severe colitis complicating pregnancy [abstract]. Am J Gastroenterol 1996;91:1975.
35. Branch DW, Scott JR. The immunology of pregnancy. In: Creasy RK, Resnick R, eds. Maternal-fetal medicine: Principles and practice, 3rd Ed. Philadelphia: WB Saunders, 1994:115-27.
36. Lemons JA, Bauer CR, Oh W, et al. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1995 through December 1996. Pediatrics 2001;107:E1.
37. Dominitz JA, Young JC, Boyko EJ. Outcomes of infants born to mothers with inflammatory bowel disease: A population-based cohort study. Am J Gastroenterol 2002;97(3):641-8.
38. Kornfeld D, Cnattingius S, Ekborn A. Pregnancy outcomes in women with inflammatory bowel disease - A population-based cohort study. Am J Obstet Gynecol 1997;177(4):942-6.
39. Moser MA, Okun NB, Mayes DC, et al. Crohn's disease, pregnancy, and birth weight. Am J Gastroenterol 2000;95:1021-6.
40. Woolfson K, Cohen Z, McLeod RS. Crohn's disease and pregnancy. Dis Colon Rectum 1990;33:869-73.
41. Fedorkow DM, Persaud D, Nimrod CA. Inflammatory bowel disease: A controlled study of late pregnancy outcome. Am J Obstet Gynecol 1989;160:998-1001.
42. Dickinson DF, Arnold R, Wilkinson JL. Congenital heart disease among 160,480 liveborn children in Liverpool, 1960 to 1969. Br Heart J 1981;46:55-62.
43. Dolara A, Manetti A. Epidemiology of congenital malformations of the heart. Acta Cardiol 1978;33:221-4.
44. Ferencz C, Rubin JD, Mc Carter RJ, et al. Congenital heart disease: Prevalence at live birth; The Baltimore-Washington Infant Study. Am J Epidemiol 1983;121:31-6.
45. Hoffman JIE, Christianson R. Congenital heart disease in a cohort of 19,502 births with long term follow-up. Am J Cardiology 1978;42:641-7.
46. Rajagopal SK. Medical Encyclopedia: Tetralogy of Fallot. U.S. National Library of Medicine and the National Institute of Health. Retrieved September 2003, Available at www.nlm.nih.gov/medlineplus/ency/article/001567.
47. Maeda J, Yamagishi H, Matsuoka R, et al. Frequent association of 22q11.2 deletion with Tetralogy of Fallot. Am J Med Genet 2000;92:269-72.
48. Arava, U.S. Package Insert, 2003.
49. Steward DR, Colodny AL, Daggett WC. Malrotation of the bowel in infants and children: A 15-year review. Surgery 1976;79:716-20.
50. Glaser DB, Dieck GS. A view from industry. In: Strom BL, ed. Pharmacoepidemiology, 3rd Ed. Chichester, England: John Wiley and Sons, 2000:91-108.
51. Kennedy DL, Goldman SA, Little RB. Spontaneous reporting in the United States. In: Strom BL, ed. Pharmacoepidemiology, 3rd Ed. Chichester, England: John Wiley and Sons, 2000:152-74.
52. Wilton LV, Pearce GL, Martin RM, et al. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynecol 1998;105:882-9.